a nuclear protein that binds to splice sites in pre-mRNA and regulates splice site selection. Binds and stabilizes cytoplasmic mRNA. Contributes to the regulation of translation by modulating the interaction between the mRNA and eukaryotic initiation factors CCAAT-containing Y-box of HLA class II genes. Component of cytoplasmic messenger ribonucleoprotein particles (mRNPs). Interacts with AKT1, SFRS9, THOC4, MSH2, XRCC5, WRN and NCL. Can bind to DNA as a homomeric form, (EFI-A)n or as a heteromeric form in association with EFI-B. Homodimer in the presence of ATP. Involved in cisplatin resistance. Seems to be a negative regulatory factor. May play a role in both transcriptional and translational regulation of spermatogenesis. Found at very low levels at day 10 and levels increase at day 15 and persist throughout adulthood. Note: This description may include information from UniProtKB.
Protein type: Transcription factor; RNA splicing; RNA-binding; RNA processing
Molecular Function: protein binding; DNA binding; RNA binding; double-stranded DNA binding; transcription factor activity; single-stranded DNA binding
Biological Process: nuclear mRNA splicing, via spliceosome; transcription from RNA polymerase II promoter; negative regulation of striated muscle cell differentiation; regulation of transcription, DNA-dependent; in utero embryonic development; RNA splicing; positive regulation of cell division; gene expression; positive regulation of transcription from RNA polymerase II promoter; negative regulation of transcription from RNA polymerase II promoter
Alt. Names/Synonyms: BP-8; CBF-A; CCAAT-binding transcription factor I subunit A; CSDA2; CSDB; DBPB; DNA-binding protein B; EFI-A; Enhancer factor I subunit A; major histocompatibility complex, class II, Y box-binding protein I; MDR-NF1; MGC104858; MGC110976; MGC117250; NSEP-1; NSEP1; nuclease sensitive element binding protein 1; Nuclease-sensitive element-binding protein 1; Y box binding protein 1; Y-box transcription factor; Y-box-binding protein 1; YB-1; YB1; YBOX1; YBX1
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.